Verona Pharma names new CFO
This article was originally published in Scrip
London-based Verona Pharma, which develops treatments for respiratory diseases, has named Richard Bungay chief financial officer – effective 5 September 2013. Mr Bungay is also part-time CEO of Chroma Therapeutics, a venture capital-backed biotechnology company developing novel small molecules for inflammation and oncology. He succeeds Danny Lowe in the position. Mr Lowe, who is based in Canada, will continue to work with Mr Bungay for an interim handover period.
You may also be interested in...
A complete response letter from the FDA in June knocked Intercept’s stock price down to 2014 levels, but perhaps the regulator is sending wider messages about NASH.
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.